title: Therapeutic HIV Peptide Vaccine.
abstract: Therapeutic vaccines aim to control chronic HIV infection and eliminate the need for lifelong antiretroviral therapy (ART). Therapeutic HIV vaccine is being pursued as part of a functional cure for HIV/AIDS. We have outlined a basic protocol for inducing new T cell immunity during chronic HIV-1 infection directed to subdominant conserved HIV-1 epitopes restricted to frequent HLA supertypes. The rationale for selecting HIV peptides and adjuvants are provided. Peptide subunit vaccines are regarded as safe due to the simplicity, quality, purity, and low toxicity. The caveat is reduced immunogenicity and hence adjuvants are included to enhance and direct the immune response. Although the vaccine has been tested in ART naïve individuals, we recommend future testing of the vaccine during (early started) ART that improves immune function and to select individuals likely to benefit. Peptides representing other epitopes may be used.
authors.affiliation: Virus R&D Laboratory, Department of Microbiology Diagnostic and Virology, Statens Serum Institut, 5 Artillerivej, Copenhagen, 2300, Denmark. AFO@ssi.dk.|Infectious Disease Research Unit, Clinical Institute, University of Southern Denmark, Odense, Denmark. AFO@ssi.dk.
authors.forename: Anders
authors.initials: A
authors.lastname: Fomsgaard
mesh_terms: D016915:AIDS Vaccines / Q000276:immunology*; D000276:Adjuvants, Immunologic; D000956:Antigens, Viral / Q000737:chemistry / Q000276:immunology*; D018604:Epitope Mapping / Q000379:methods; D018984:Epitopes, T-Lymphocyte / Q000276:immunology; D015658:HIV Infections / Q000276:immunology* / Q000517:prevention & control / Q000628:therapy / Q000821:virology; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D010455:Peptides / Q000276:immunology*; D022223:Vaccines, Subunit / Q000276:immunology*
chemical_list: D016915:AIDS Vaccines; D000276:Adjuvants, Immunologic; D000956:Antigens, Viral; D018984:Epitopes, T-Lymphocyte; D010455:Peptides; D022223:Vaccines, Subunit
keywords: Adjuvant; CD8 T cells; Cytotoxic T lymphocytes; Functional cure; HIV-1; Human trial; Peptide; Therapeutic vaccine